SINGAPORE, Oct. 21 /Xinhua-PRNewswire/ -- Biosensors International Group, Ltd., ("Biosensors" or the "Company", Bloomberg: BIG SP) is pleased to announce that it will be participating in the Cardiovascular Research Foundation's eighteenth annual Transcatheter Cardiovascular Therapeutics ("TCT") scientific symposium, which is being held from 22 - 27 October 2006 in Washington D.C. Biosensors will occupy booth #1450 at the Washington Convention Center. Below is a schedule of major events for Biosensors at TCT (all times are in U.S. Eastern Daylight Time): Tuesday, Oct. 24 -- Breakfast Meeting: 7- 8 a.m.; Washington Convention Center; Room 150B. "The New Generation of Drug-Eluting Stents - Will they Meet the Clinical Need?" Moderated by Dr. David Holmes, Jr., Mayo Clinic, Rochester. This breakfast meeting, sponsored by Biosensors and its partner Xtent Inc., will offer a comprehensive look at the safety issues of polymer on drug-eluting stents and how the two companies' drug-eluting stent technologies fit into this safety landscape. Speakers include: Dr. Renu Virmani, CVPath, Gaithersburg; Dr. Miodrag Ostojic, Clinical Center of Serbia, Belgrade, Serbia; and Dr. Stephan Windecker, Swiss Cardiovascular Center Bern, Bern, Switzerland. The meeting will be available via webcast at Biosensors' corporate website at http://www.biosensors.com. Thursday, Oct. 26 -- Scientific Symposia: The Drug-Eluting Stent Summit 2006: 2:00-3:50 p.m.; Washington Convention Center, Ballroom C, Level 3. Dr. David Holmes, Jr. will present on Biosensors' BioMatrix(R) Biolimus-eluting stent clinical programs - STEALTH, BEACON and LEADERS trials. Dr. Thomas Ischinger will also present results and outcomes from Biosensors' EAGLE study. Biosensors' technology will also be presented through its partners Terumo Corporation, Xtent Inc., and Devax Inc. A schedule of the major events for Biosensors' partners during TCT is as follows: Tuesday, Oct. 24 -- NOBORI 1 clinical trial results: 12.45 p.m.; Washington Convention Center, Main Arena. Dr. Bernard Chevalier will present the nine-month clinical and angiographic follow-up results of Terumo's NOBORI 1 clinical trial. NOBORI 1 is a prospective, randomized trial of Biolimus A9(R) and Paclitaxel-eluting stents. Wednesday, Oct. 25 -- Scientific Presentations: Coronary Stent Design and New Clinical Trial Insights (Washington Convention Center, Room 145AB) -- 9.45 a.m. Dr. Charles Simonton will present on Xtent Inc.'s novel modular design for customized stenting -- 11.35 a.m. Dr. Fausto Feres will present on Devax Inc.'s Axxess and Axxess Plus stents -- 11.59 a.m. Dr. Akiyoshi Miyazawa et al. will present on the intravascular ultrasound results of the Devax Inc.'s Axxess Plus stent. Thursday, Oct. 26 Scientific Symposia: The Drug-Eluting Stent Summit 2006 (Washington Convention Center, Ballroom C, Level 3) -- 2.15 p.m. Dr. Bernard Chevalier will present data on Terumo's NOBORI Biolimus-eluting stent clinical trials -- 2.25 p.m. Dr. Stefan Verheye will present Devax's multi-center registry results and outcomes of its Axxess self- expanding bifurcation Biolimus-eluting stent in the left main subset -- 2.35 p.m. Prof. Eberhard Grube will present on Xtent's CUSTOM modular Biolimus-eluting stent. Media Contact Biosensors International Group Ms Tina Lim, Executive, Corporate Communications Tel: (65) 6213 5712 Email: email@example.com Media Relations / Investor Relations Firm United States Allen & Caron Inc. Mr. Matt Clawson Executive Vice President, Investor Relations Tel: (1) 949 474 4300 Email: firstname.lastname@example.org About Biosensors International Group, Ltd. Biosensors develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. Biosensors is well-positioned to emerge as a leader in drug-eluting stents, an evolving therapy that is rapidly gaining market share from traditional therapies such as bare-metal stenting and open-heart surgery. Biosensors has internally developed technology to address each component of a drug-eluting stent system, including a stent, a stent delivery catheter, a biodegradable polymer and a proprietary anti-restenotic drug. It is pursuing two separate drug-eluting stent programs, BioMatrix(R) and Axxion(TM), and has licensed aspects of its drug-eluting stent technology to four companies. Forward Looking Statements Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward- looking statements generally can be identified by the use of forward-looking terminology, such as "may," "will," "expect," "intend," "estimate," "anticipate," "believe," "project" or "continue" or the negative thereof or other similar words. All forward-looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward- looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.
SOURCE Biosensors International Group, Ltd.